The non-invasive Masimo O3® Regional Oximeter System and accessories are indicated for use as an adjunct monitor of regional hemoglobin oxygen saturation of blood (rSO2) in the tissue under the sensors in patients in healthcare environments. The O3® Regional Oximeter is only to be used with Masimo O3 sensors. The use of any other sensor is not supported or recommended by Masimo and could give erroneous results.

When used with the O3 Adult Sensor, the O3® Regional Oximeter is indicated for measuring absolute and trending regional hemoglobin oxygen saturation of blood (tSO2) on cerebral sites and trending rSO2 on non-cerebral sites in adults > 40kg.

When used with the O3 Pediatric Sensor, the O3® Regional Oximeter for measuring absolute and trending regional hemoglobin oxygen saturation of blood (rSO2) on cerebral sites and trending rSO2 on non-cerebral sites in pediatrics ≥ 5 kg and < 40 kg.

When used with the O3 Neonatal Sensor, the O3® Regional Oximeter is indicated for measuring regional hemoglobin oxygen saturation of blood (tSO2) on cerebral sites and trending rSO2 on non-cerebral sites in neonates < 10kg.

The AcHb, AO2Hb, AHHb provided as part of the Masimo O3 are indicated for the monitoring of the relative hemoglobin changes of oxygenated hemoglobin (△O2Hb), deoxygenated hemoglobin (△HHb), and total hemoglobin (△cHb) as measured from the Masimo O3 sensor when applied to the cerebral tissue in adults.

Device Description

The Masimo O3 Regional Oximeter is a noninvasive regional oximeter designed to continuously measure and monitor regional hemoglobin oxygen saturation under the sensor. The Masimo O3 Regional Oximeter consists of the following components: 03 Module, O3 Sensors (e.g. O3 Adult, O3 Pediatric, and O3 Infant/Neonatal Sensors), and a display monitor (e.g. Root) same as those cleared under K182429.

The O3 System provides the following key measurements:

Regional Oxygenation (rSO2): Regional tissue oxygenation level in the deep tissue local to the sensor site.
Delta Baseline (Abase): Relative difference in rSO2 with respect to baseline rSO2.
Area Under the Limit (AUL index): Index that quantifies the duration (amount of time) the patient stays below rSO2 low alarm limit and depth (refers to the gap between the patient's rSO2 level and the rSO2 low alarm limit) of patient's stay below the user-defined rSO2 low alarm limit (LAL)
Delta SpO2 (ASpO2): The difference between SpO2 and rSO2. The source of SpO2 is from peripheral SpO2 measurement (using pulse oximeter).
Delta HHb (ΔHHb): a measure of the relative change in deoxygenated hemoglobin.
Delta 02Hb (ΔΟ2Hb): a measure of the relative change in the oxygenated hemoglobin.
Delta cHb (ΔcHb): the sum of the Delta HHbi and Delta O2Hbi, as a measure of the relative change in the total hemoglobin.

AI/ML Overview

The provided text is a 510(k) premarket notification from Masimo Corporation for their O3 Regional Oximeter System. The purpose of this submission is to expand the indications for use of an existing device. It does not describe a study that validates the device meets acceptance criteria in the format typically seen for novel AI/ML devices or diagnostic accuracy studies. Instead, it aims to demonstrate substantial equivalence to a predicate device, particularly for expanded indications.

Therefore, many of the requested details about acceptance criteria, ground truth, expert adjudication, MRMC studies, and training set information are not explicitly present in this document because the nature of the submission (510(k) for expanded indications) focuses on demonstrating equivalence rather than a full de novo validation of a new device's performance against specific clinical endpoints with granular data.

However, I can extract the relevant performance specifications and describe the studies conducted to support the expanded indications based on the information available.

Here's a breakdown of the requested information based on the provided document:

1. A table of acceptance criteria and the reported device performance

The document doesn't present "acceptance criteria" in the typical sense of a diagnostic claim (e.g., sensitivity, specificity, AUC). Instead, it provides performance specifications for the regional oximeter and describes studies designed to demonstrate that the device performs comparably to reference methods or predicate devices for the expanded indications.

The key performance specifications listed are:

Feature	Specification
Performance (Arms)
Non-Cerebral Oxygen Monitoring
rSO2 Trending (Adult, Pediatric, and Neonate)	3% for SavO2 of 45%-85%
Cerebral Oxygen Monitoring
rSO2 Absolute (Adult ≥ 40 kg)	4% for SavO2 of 45%-85%
rSO2 Absolute (Pediatric ≥ 5 kg and < 40 kg)	5% for SavO2 of 45%-85%
rSO2 Trending (Adult, Pediatric, and Neonate)	3% for SavO2 of 45%-85%

Reported Device Performance: The document states that the studies "supported the substantial equivalence" and "supported there are no significant technological characteristic differences." It does not provide specific numerical outcomes (e.g., mean difference, bias, precision) from these studies comparable to the specifications listed above for the expanded indications. The focus of the 510(k) is often on the conclusion of equivalence rather than granular performance metrics from the validation studies themselves. The provided "Specification" table appears to be the design specification rather than the measured performance from the described clinical studies for the expanded indications.

2. Sample sizes used for the test set and the data provenance

The document describes three clinical studies:

Study 1 (rSO2 Trending, Non-Cerebral):
- Sample Size: 42 adult subjects.
- Data Provenance: Not explicitly stated (e.g., country of origin, hospital site), but it's a prospective controlled desaturation study.
Study 2 (rSO2 Trending Comparison to Other Cleared Devices, Non-Cerebral):
- Sample Size: 59 adult subjects.
- Data Provenance: Not explicitly stated, but it's a prospective controlled desaturation study.
Study 3 (ΔO2Hb, ΔHHb, ΔcHb Trending Comparison, Cerebral):
- Sample Size: 22 adult subjects.
- Data Provenance: Not explicitly stated, but it's a prospective hemodilution protocol study.

All studies appear to be prospective as they involved controlled physiological interventions (step-wise desaturation, hemodilution) on live subjects.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

The concept of "experts" establish ground truth is not applicable to these studies. The studies are evaluating a physiological monitoring device against a direct physiological reference or similar devices.

For rSO2 trending studies, the "ground truth" for oxygen saturation decrease was confirmed by arterial oxygen saturation (SpO2), which is a direct physiological measurement, not an expert interpretation.
For the hemoglobin change study, the "ground truth" for hemoglobin concentration changes was established via a hemodilution protocol, a controlled physiological intervention designed to induce changes in blood volume and thus, relative hemoglobin concentrations.

4. Adjudication method for the test set

Not applicable. As the ground truth is established by physiological measurements or controlled interventions, there is no need for expert adjudication in the classic sense found in image-based diagnostic studies.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a physiological monitor, not an AI/ML diagnostic interpretation tool that assists human readers. Therefore, an MRMC study and analysis of human reader improvement with AI assistance are not relevant to this technology.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The device itself is the "standalone algorithm" in terms of its measurement capabilities. The studies described are evaluations of the device's performance in measuring the specified physiological parameters. These are not "human-in-the-loop" studies but rather direct performance evaluations of the hardware and integrated algorithms.

7. The type of ground truth used

The ground truth used in these studies was physiological data from direct measurements or controlled interventions:

For rSO2 trending on non-cerebral sites, the reference was arterial oxygen saturation (SpO2).
For trending of ΔO2Hb, ΔHHb, and ΔcHb, the changes were induced through a hemodilution protocol, serving as the "ground truth" for induced relative changes in hemoglobin levels.

8. The sample size for the training set

Not applicable. This document describes clinical validation studies for an expanded indication of an existing physiological monitoring device. It does not mention any "training set" in the context of machine learning model development. This is a traditional medical device, not an AI/ML device that requires a distinct training/test set methodology for algorithm development or performance evaluation.

9. How the ground truth for the training set was established

Not applicable. As explained above, there is no mention of a "training set" for an AI/ML model in this submission.

Summary

{0}------------------------------------------------

August 29, 2020

Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA text logo on the right. The FDA text logo is in blue and includes the letters "FDA" followed by "U.S. FOOD & DRUG ADMINISTRATION" in a stacked format.

Masimo Corporation Sindura Penubarthi Regulatory Affairs Manager 52 Discovery Irvine. California 92618

Re: K201432

Trade/Device Name: Masimo O3 Regional Oximeter System Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: MUD Dated: May 29, 2020 Received: June 1, 2020

Dear Sindura Penubarthi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Colin Kejing Chen Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K201432

Device Name Masimo O3 Regional Oximeter System

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)	☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features a red circle with a white checkmark inside, positioned to the left of the company name, "Masimo," which is written in a simple, sans-serif font. The overall design is clean and modern, reflecting the company's focus on innovation in healthcare.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

Submitter and Address ofManufacturing Facility:	Masimo Corporation52 DiscoveryIrvine, CA 92618Phone: (949) 297-7541FAX: (949) 297-7592
Date:	August 29, 2020
Contact:	Sindura PenubarthiRegulatory Affairs Manager
Trade Name:	Masimo O3 Regional Oximeter System
Common Name:	Oximeter, Tissue Saturation
Classification Regulation/Product Code:	21 CFR 870.2700, Class II/ MUD
Establishment RegistrationNumber:	3011353843
Reason for PremarketNotification:	Expanded indications for use
Predicate Device:	K182429 – Masimo O3 Regional Oximeter System
Reference Predicate	K091224 - Somanetics INVOS 5100CK112820 - CAS Medical ForeSight EliteK113215 – Nonin Medical Model 7600K162117 -- NIRO-200NX
Performance Standards	There are no performance standards pursuant to Section 514 of theFood, Drug and Cosmetic Act for the above device.

1. Device Description

The O3 System provides the following key measurements:

Regional Oxygenation (rSO2): Regional tissue oxygenation level in the deep tissue local to the sensor site.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features the company name in a bold, sans-serif font. To the left of the name is a stylized, red, circular symbol with a white checkmark-like shape inside. The overall design is clean and modern, reflecting the company's focus on innovation in healthcare.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

Delta Baseline (Abase): Relative difference in rSO2 with respect to baseline rSO2. ●
Area Under the Limit (AUL index): Index that quantifies the duration (amount of time) the patient stays below rSO2 low alarm limit and depth (refers to the gap between the patient's rSO2 level and the rSO2 low alarm limit) of patient's stay below the user-defined rSO2 low alarm limit (LAL)
Delta SpO2 (ASpO2): The difference between SpO2 and rSO2. The source of SpO2 is from ● peripheral SpO2 measurement (using pulse oximeter).
Delta HHb (ΔHHb): a measure of the relative change in deoxygenated hemoglobin.
Delta 02Hb (ΔΟ2Hb): a measure of the relative change in the oxygenated hemoglobin. ●
Delta cHb (ΔcHb): the sum of the Delta HHbi and Delta O2Hbi, as a measure of the relative . change in the total hemoglobin.

The performance specifications are included in table below:

Feature	Specification
Performance (Arms)
Non-Cerebral Oxygen Monitoring
rSO2 Trending (Adult, Pediatric, and Neonate)	3% for SavO2 of 45%-85%
Cerebral Oxygen Monitoring
rSO2 Absolute (Adult ≥ 40 kg)	4% for SavO2 of 45%-85%
rSO2 Absolute (Pediatric ≥ 5 kg and < 40 kg)	5% for SavO2 of 45%-85%
rSO2 Trending (Adult, Pediatric, and Neonate)	3% for SavO2 of 45%-85%

Table 5.1.1

2. Intended Use/ Indications For Use

The non-invasive Masimo O3® Regional Oximeter System and accessories are indicated for use as an adjunct monitor of regional hemoglobin oxygen saturation of blood (rSO2) in the tissue under the sensors in patients in healthcare environments. The 03% Regional Oximeter is only to be used with Masimo O3 sensors. The use of any other sensor is not supported or recommended by Masimo and could give erroneous results.

When used with the O3 Pediatric Sensor, the O3® Regional Oximeter is indicated for measuring absolute and trending regional hemoglobin oxygen saturation of blood (tSO2) on cerebral sites and trending tSO2 on non-cerebral sites in pediatrics ≥ 5 kg and < 40 kg.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features a stylized red checkmark to the left of the company name, "Masimo," which is written in a simple, sans-serif font. The checkmark is a vibrant red color, while the company name is in black.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

When used with the 03 Neonatal Sensor, the 03% Regional Oximeter is indicated for measuring only trending regional hemoglobin oxygen saturation of blood (tSO2) on cerebral sites and trending rSO2 on non-cerebral sites in neonates < 10kg.

The ΔcHb, ΔΟ2Hb, ΔΗΗb provided as part of the Masimo Ο3 are indicated for the monitoring of the relative change of oxygenated hemoglobin (△○2Hb), deoxygenated hemoglobin (△HHb), and total hemoglobin (AcHb) as measured from the Masimo O3 sensor when applied to the cerebral tissue in adults.

3. Technological Characteristics

Principle of Operation

The principle of operation for the 03 Regional Oximeter is based on multi-distance diffusion spectroscopy. Multi-distance diffusion spectroscopy used in the O3 Regional Oximeter relies on the use of differing wavelengths of light that is diffused into a cross-section of tissue consisting of microvasculature (a mixed bed of arterioles, capillaries and venules) and analyzes the light detected after having passed through the tissue from detectors at two different distances from the light source.

Mechanism of Action for Achieving the Intended Effect

The O3 sensor is noninvasively applied to the patient to collect the patient's physiological signals which are processed by the O3 Module. The processed data consists of the rSO2 measurements which are then communicated and displayed on the host/backboard device.

4. Summary of Technological Characteristics of a subject device to the predicate

Similarities and Differences between Subject Device, O3 Regional Oximeter and Predicate Device, 03 Regional Oximeter (K182429)

The subject device, O3 Regional Oximeter, and the predicate device, O3 Regional Oximeter (K182429), have the following key similarities:

Same intended use for regional oxygen tissue saturation; ●
Same principle of operations:
Same hardware including critical components (e.g., O3 Sensors); ●
. Same performance specifications for absolute and trending rSO2; and
Same mechanical and environmental specifications.

The subject device, O3 Regional Oximeter, and the predicate device, O3 Regional Oximeter (K182429), have the following key differences:

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features the company name in a bold, sans-serif font, with the letters "MASIMO" clearly visible. To the left of the name is a stylized, circular graphic element in red, which appears to be a stylized waveform or pulse, possibly representing the company's focus on monitoring vital signs. The overall design is clean and professional, reflecting the company's presence in the healthcare industry.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

· The subject device is indicated for an expanded indication for monitoring tissue oxygen saturation in non-cerebral application sites, whereas the predicate is cleared for monitoring cerebral application sites.
· The subject device is indicated for an expanded indication for monitoring of the relative change of oxygenated hemoglobin (ΔΟ2Hb), deoxygenated hemoglobin (ΔΗΗΒ), and total hemoglobin (ΔcHb) as measured from the Masimo O3 sensor when applied to the cerebral tissue in adults.

The substantial equivalence of the subject device to the predicate device is supported through the use of clinical and non-clinical testing to support the difference does not raise different questions of safety and effectiveness.

ട്. Performance Data

Biocompatibility Testing

Biocompatibility testing was not required for this submission as there was no change to the materials from the previously cleared O3 sensors (K182429). The cleared sensors were previously evaluated in accordance to ISO 10993 and as a result, the acceptability of the biocompatibility risks for the subject device was determined based on the testing conducted on the predicate sensors.

Electromagnetic Compatibility, Electrical Safety, Environmental, Mechanical and Cleaning

Additional Electromagnetic Compatibility, Electrical Safety, Environmental, Mechanical and Cleaning testing for this submission was not required as there was no change to the components from the previously cleared 03 Regional Oximeter (K182429).

Software Verification and Validation Testing

As part of this submission, additional Software verification and validation testing was conducted and documented as recommended by FDA's Guidance, Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, dated May 11, 2005. The software for this device was still considered a "moderate" level of concern. The testing was found to support the substantial equivalence of the subject device.

Wireless and Cybersecurity Testing

Additional Wireless and Cybersecurity testing was not required as part of this submission as there were no changes to the wireless capabilities or communication capabilities of the subject device

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features a stylized red checkmark to the left of the company name, "Masimo," which is written in a simple, sans-serif font. The checkmark is partially obscured by the letter "M" in Masimo.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

from the previously cleared O3 Regional Oximeter (K182429). As a result, the acceptability of the wireless and cybersecurity risks for the subject device were determined based on the testing previously conducted as part of the predicate device clearance.

Human Factors and Usability Testing

Additional Human Factors and Usability was not required as part of this submission as there was no change to the critical user related tasks or need for additional usability risk mitigations for the subject device from the previously cleared predicate device O3 Regional Oximeter (K182429). The human factor and usability consideration are the same as the previously cleared. As a result, the acceptability of the Human factors/ Usability risk for the subject device was determined based upon the testing conducted as part of the predicate device. The cleared predicate 03 Regional Oximeter had previously been tested in accordance with the FDA Guidance, Applying Human Factors and Usability Engineering to Medical Devices, February 3, 2016.

Non-clinical Performance Testing

Non-clinical performance testing was conducted comparing the performance of the subject device to a FDA cleared regional oximeter for use on non-cerebral sites using a reference phantom. The phantom allowed the simulation of differing levels of oxygenation in order to characterize the performance of both regional oximeters to changes in tissue oxygen levels. The study supported the substantial equivalence of the O3 to FDA cleared regional oximeters in the ability to respond to oxygen level changes.

Clinical Testing

To support the substantial equivalence of the subject device with the expanded indications for use, three clinical studies were conducted.

One clinical study compared the trending ability of the O3 Regional Oximeter to changes in oxygen saturation while the cleared O3 Adult, O3 Pediatric, and O3 Infant/Neonatal Sensors were applied to a non-cerebral application site. The study included 42 adult subjects whose oxygen saturations were decreased in a step-wise controlled desaturation to 70% SpO2. The study used the arterial oxygen saturation (SpO2) as a reference to confirm the actual decrease in the oxygen saturation. The study supported the transferability of the technological characteristics of the O3 Regional Oximeter on non-cerebral application sites.

The second study compared the trending performance of the O3 Regional Oximeter to other cleared regional oximeters using the cleared O3 Adult, O3 Pediatric, and O3 Infant/Neonatal Sensors applied to a non-cerebral application site. The study included 59 adult subjects whose oxygen saturations were decreased in a step-wise controlled desaturation to 70% SpO2. The study supported there are no significant technological characteristic differences in the trending

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image shows the logo for Masimo, a medical technology company. The logo features the company name in a bold, sans-serif font. To the left of the name is a red circular symbol with a white checkmark inside, which is a stylized representation of a heartbeat or pulse wave. The overall design is clean and modern, reflecting the company's focus on innovation in healthcare.

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

performance of the 03 Regional Oximeter when applied on non-cerebral application sites using other cleared regional oximeters as a performance reference.

The third study compared the trending performance of the O3 Regional Oximeter to relative changes in oxyhemoglobin, deoxyhemoglobin and total hemoglobin levels (ΔΟ2Ηb, ΔΗΗb and ΔcHb) to that of a reference predicate with similar features using the cleared O3 Adult sensors applied to the cerebral application site. This study included 22 adult subjects whose hemoglobin concentrations were varied using a hemodilution protocol. The study supported there are no significant technological characteristic differences in trending the performance of O3 Regional Oximeter to that of the reference predicate.

Conclusion 6.

The data provided as part of this submission supports the substantial equivalence of the subject device.

{9}------------------------------------------------

Image /page/9/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of the word "Masimo" in a bold, sans-serif font, with a stylized red symbol to the left of the word. To the right of the logo is the text "MASIMO CORPORATION" in a smaller, sans-serif font, followed by the address "52 Discovery, Irvine, CA 92618".

MASIMO CORPORATION
52 Discovery
Irvine, CA 92618

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).